Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus THEOLAIR SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus THEOLAIR SR.
FORADIL vs THEOLAIR-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator